<DOC>
	<DOCNO>NCT01437657</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , parallel group study evaluate safety efficacy RO4917523 adjunctive therapy patient major depressive disorder inadequate response ongoing antidepressant therapy . Anticipated time study treatment 6 week 3-week follow-up .</brief_summary>
	<brief_title>MARIGOLD Study : A Study RO4917523 Versus Placebo Adjunctive Therapy Patients With Major Depressive Disorder Inadequate Response Ongoing Antidepressant Therapy</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>Adult patient , 18 70 year age time inform consent Major depressive disorder without psychotic feature define DSMIVTR criterion Inadequate response ongoing antidepressant treatment , define protocol Body mass index ( BMI ) 18 38 kg/m2 inclusive Currently receive treatment combination antidepressant ( two ) , adjunctive potentiating treatment define protocol Previously receive RO4917523 History failure , utilization current episode Electroconvulsive Therapy ( ECT ) repetitive Transcranial Magnetic Stimulation ( rTMS ) History use time Vagus Nerve Stimulation ( VNS ) Deep Brain Stimulation ( DBS ) Current past history bipolar disorder ( e.g . manic , hypomanic , mixed episode ) Pregnant lactate woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>